To date, anti-HER2 monotherapy, such as trastuzumab monotherapy, is less effective against HER2-overexpressed pancreatic cancer [74], but combination therapy with HER2 and other ERBB families is promising. Here, ERBB2 is linked to pancreatic neoplasm.